Search results
Results from the WOW.Com Content Network
Erythropoiesis (from Greek 'erythro' meaning "red" and 'poiesis' "to make") is the process which produces red blood cells (erythrocytes), which is the development from erythropoietic stem cell to mature red blood cell. [1] It is stimulated by decreased O 2 in circulation, which is detected by the kidneys, which then secrete the hormone ...
[8] [9] Epoetin alfa is an erythropoiesis-stimulating agent. [8] It stimulates erythropoiesis (increasing red blood cell levels) and is used to treat anemia, commonly associated with chronic kidney failure and cancer chemotherapy. Epoetin alfa is developed by Amgen. [8] It is on the World Health Organization's List of Essential Medicines. [10]
CFU-GEMM is a colony forming unit that generates myeloid cells.CFU-GEMM cells are the oligopotential progenitor cells [1] [2] for myeloid cells; they are thus also called common myeloid progenitor cells or myeloid stem cells.
Erythropoiesis-stimulating agents (ESA) are medications which stimulate the bone marrow to make red blood cells. [1] They are used to treat anemia due to end stage kidney disease, chemotherapy, major surgery, or certain treatments in HIV/AIDS. [1] [2] In these situations they decrease the need for blood transfusions. [2]
Megakaryocyte–erythroid progenitor cells must commit to becoming either platelet-producing megakaryocytes via megakaryopoiesis or erythrocyte-producing erythroblasts via erythropoiesis. [ 2 ] [ 3 ] Most of the blood cells produced in the bone marrow during hematopoiesis come from megakaryocyte–erythroid progenitor cells.
Darbepoetin alfa / d ɑːr b ə ˈ p oʊ ɪ t ɪ n / is a re-engineered form of erythropoietin containing 5 amino acid changes (N30, T32, V87, N88, T90) resulting in the creation of 2 new sites for N-linked carbohydrate addition. It has a 3-fold longer serum half-life compared to epoetin alpha and epoetin beta.
It can describe an increase in the number of red blood cells [1] ("absolute polycythemia") or to a decrease in the volume of plasma ("relative polycythemia"). [2] Absolute polycythemia can be due to genetic mutations in the bone marrow ("primary polycythemia"), physiologic adaptations to one's environment, medications, and/or other health ...
Dyserythropoiesis refers to the defective development of red blood cells, also called erythrocytes. [1] This problem can be congenital, acquired, or inherited. [2] Some red blood cells may be destroyed within the bone marrow during the maturation process, whereas others can enter the circulation with abnormalities. [3]